Anti-inflammatory effects of systemic anti-tumour necrosis factor α treatment in human/murine SCID arthritis

Annals of the Rheumatic Diseases

Volumn 58, Issue 7, 1999, Pages 428-434

  Schädlich, Hiltrud ^c   Ermann, Jörg ^c   Biskop, Maria ^a   Falk, Werner ^c   Sperling, Frauke ^c   Jüngel, Astrid ^c   Lehmann, Jörg ^c   Emmrich, Frank ^c   Sack, Ulrich ^b  

^a Private Practice   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CASE REPORT; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RHEUMATOID ARTHRITIS;

EID: 0032982341     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.58.7.428     Document Type: Article

References (45)

1. 1 Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996;14:397-40.
2. 2 Husby G, Williams RC. Synovial localization of tumor necrosis factor in patients with rheumatoid arthritis. J Autoimmun 1988,1:363-71.
3. 3 Gräfe H, Stiehl P. Untersuchungen zu Vorkommen und Verteilung von TNF-alpha und TNF-beta in Synovialmembran (SM) von Patienten mit Rheumatoider Arthritis (RA). [Abstract]. Z Zellforsch Mikrosk Anat 1994;53:43.
4. 4 Chu CQ, Field M, Allard S, Abney E, Feldmann M, Maini RN. Detection of cytokines at the cartilage/pannus junction in patients with rheumatoid arthritis: implications for the role of cytokines in cartilage destruction and repair. Br J Rheumatol 1992;31:653-61.
5. 5 Saklatvala J. Tumour necrosis factor alpha stimulates resorption and inhibits synthesis of proteoglycan in cartilage. Nature 1986;322:547-9.
6. 6 Alsalameh S, Kalden JR, Burmester GR. The role of cytokines and growth factors in rheumatoid joint destruction. Z Rheumatol 1991;50:347-59.
7. 7 Feldmann M, Elliott MJ, Brennan FM, Maini RN. Use of anti-tumor necrosis factor antibodies in rheumatoid arthritis. J Interferon Res 1994;14:299-300.
8. 8 Rankin EC, Choy EH, Kassimos D, et al. The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis. Br J Rheumatol 1995;34:334-42.
9. 9 Marinova-Mutafchieva L, Williams RO, Mason LJ, Mauri C, Feldmann M, Maini RN. Dynamics of proinflammatory cytokine expression in the joints of mice with collagen-induced arthritis (CIA). Clin Exp Immunol 1997;107: 507-12.
10. 10 Williams RO, Mauri C, Mason LJ, et al. Therapeutic actions of cyclosporine and anti-tumor necrosis factor alpha in collagen-induced arthritis and the effect of combination therapy. Arthritis Rheum 1998;41:1806-12.
11. 11 Mussener A, Litton MJ, Lindroos E, Klareskog L. Cytokine production in synovial tissue of mice with collagen-induced arthritis (CIA). Clin Exp Immunol 1997;107:485-93.
12. 12 Lewthwaite J, Blake S, Hardingham T, et al. Role of TNF alpha in the induction of antigen induced arthritis in the rabbit and the anti-arthritic effect of species specific TNF alpha neutralising monoclonal antibodies. Ann Rheum Dis 1995;54:366-74.
13. 13 Beech JT, Thompson SJ. Anti-tumour necrosis factor therapy ameliorates joint disease in a chronic model of inflammatory arthritis. [Letter]. Br J Rheumatol 1997;36: 1129
14. 14 Cooper WO, Fava RA, Gates CA, Cremer MA, Townes AS. Acceleration of onset of collagen-induced arthritis by intra-articular injection of tumour necrosis factor or transforming growth factor-beta. Clin Exp Immunol 1992;89: 244-50.
15. 15 Brahn E, Peacock DJ, Banquerigo ML, Liu DY. Effects of tumor necrosis factor alpha (TNF-alpha) on collagen arthritis. Lymphokine and Cytokine Research 1992;11: 253-6.
16. 16 Keffer J, Probert L, Cazlaris H, et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J 1991;10:4025-31.
17. 17 Butler DM, Malfait AM, Mason LJ, et al. DBA/1 mice expressing the human TNF-alpha transgene develop a severe, erosive arthritis: characterization of the cytokine cascade and cellular composition. J Immunol 1997;159: 2867-76.
18. 18 Sack U, Kuhn H, Ermann J, et al. Synovial tissue implants from patients with rheumatoid arthritis cause cartilage destruction in knee joints of SCID.bg mice. J Rheumatol 1994;21:10-16.
19. 19 Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31:315-24.
20. 20 Stiehl P. Histologie der Rheumatoid-Arthritis. Beitrag zur diagnostischen und pathogenetischen Heterogenität, zur Aktivitätsdiagnose und zur Prognose. In: Sack U, ed. Arthritiden. Lengerich: Pabst Science Publishers, 1997; 188-200.
21. 21 Kuhn H, Ermann J, Sack U. Modulation of hu/mu severe combined immunodeficient (SCID) mouse arthritis by local application of human recombinant IL-1beta, IL- 2 and IL-6. Clin Exp Immunol 1997;107:96-102.
22. 22 Bosma GC, Fried M, Custer RP, Carroll A, Gibson DM, Bosma MJ. Evidence of functional lymphocytes in some (leaky) scid mice. J Exp Med 1988;167:1016-33.
23. 23 Kojouhatoff G, Hans W, Obermeier F, et al. Neutralization of tumour necrosis factor (TNF) but not of IL-1 reduces inflammation in chronic dextran sulphate sodium-induced colitis in mice. Clin Exp Immunol 1997;107:353-8.
24. 24 Echtenacher B, Falk W, Mannel DN, Krammer PH. Requirement of endogenous tumor necrosis factor/cachectin for recovery from experimental peritonitis. J Immunol 1990;145:3762-6.
25. 25 Serban D, Rordorf-Adam C. Quantitation of serum amyloid P component by an enzyme-linked immunoassay. J Immunol Methods 1986;90:159-64.
26. 26 Rijntjes NV, van de Putte LB, van der Pol M, Guelen PJ. Cryosectioning of undecalcified tissues for immunofluorescence. J Immunol Methods 1979;30:263-8.
27. 27 Sack U, Kuhn H, Kampfer I, et al. Orthotopic implantation of inflamed synovial tissue from RA patients induces a characteristic arthritis in immunodeficient (SCID) mice. J Autoimmun 1996;9:51-8.
28. 28 Sack U, Kuhn H, Ermann J, et al. Synovial tissue implants from patients with rheumatoid arthritis cause cartilage destruction in knee joints of SCID.bg mice. J Rheumatol 1994;21:10-16.
29. 29 Ulfgren AK, Lindblad S, Klareskog L, Andersson J, Andersson U. Detection of cytokine producing cells in the synovial membrane from patients with rheumatoid arthritis. Ann Rheum Dis 1995;54:654-61.
30. 30 Sack U, Kuhn H, Kampfer I, et al. Orthotopic implantation of inflamed synovial tissue from RA patients induces a characteristic arthritis in immunodeficient (SCID) mice. J Autoimmun 1996;9:51-8.
31. 31 Williams RO, Feldmann M, Maini RN. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci USA 1992;89: 9784-8.
32. 32 Brennan FM, Chantry D, Jackson A, Maini RN, Feldmann M. Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 1989;ii:244-7.
33. 33 Hirano T. Interleukin-6 and its relation to inflammation and disease. Clin Immunol Immunopathol 1992;62;S6-5
34. 34 Kuhn H, Ermann J, Sack U. Modulation of hu/mu severe combined immunodeficient (SCID) mouse arthritis by local application of human recombinant IL-1beta, IL- 2 and IL-6. Clin Exp Immunol 1997;107:96-102.
35. 35 Mihara M, Ikuta M, Koishihara Y, Ohsugi Y. Interleukin 6 inhibits delayed-type hypersensitivity and the development of adjuvant arthritis. Eur J Immunol. 1991;21:2327-31.
36. 36 Van De Loo FA, Kuiper S, van Enckevort FH, Arntz OJ, van den Berg WB. Interleukin-6 reduces cartilage destruction during experimental arthritis. A study in interleukin-6-deficient mice. Am J Pathol 1997;151:177-91.
37. 37 van Lent PL, Van De Loo FA, Holthuysen AE, van den Bersselaar LA, Vermeer H, van den Berg WB. Major role for interleukin 1 but not for tumor necrosis factor in early cartilage damage in immune complex arthritis in mice. J Rheumatol 1995;22:2250-8.
38. 38 Tilg H, Trehu E, Atkins MB, Dinarello CA, Mier JW, Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood 1994;83: 113-18.
39. 39 Emery P, Luqmani R. The validity of surrogate markers in rheumatic disease. Br J Rheumatol 1993;32 (suppl 3):3-8.
40. 10 Le PT, Mortensen RF. Induction and regulation by monokines of hepatic synthesis of the mouse serum amyloid P-component (SAP). J Immunol 1986;136:2526-33.
41. 41 Wendling D, Racadot E, Wijdenes J. Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody. J Rheumatol 1993;20:259-62.
42. 42 Thorbecke GJ, Shah R, Leu CH, Kuruvilla AP, Hardison AM, Palladino MA. Involvement of endogenous tumor necrosis factor alpha and transforming growth factor beta during induction of collagen type II arthritis in mice. Proc Natl Acad Sci USA 1992;89:7375-9.
43. 43 Piguet PF, Grau GE, Vesin C, Loetscher H, Gentz R, Lesslauer W. Evolution of collagen arthritis in mice is arrested by treatment with anti-tumour necrosis factor (TNF) antibody or a recombinant soluble TNF receptor. Immunology 1992;77:510-14.
44. 44 Issekutz AC, Meager A, Ouerness IG, Issekutz TB. The role of tumour necrosis factor-alpha and IL-1 in polymorpho-nuclear leucocyte and T lymphocyte recruitment to joint inflammation in adjuvant arthritis. Clin Exp Immunol 1994;97:26-32.
45. 45 Nezuka T, Matsuno H, Uzuki M, Saeki Y, Tsuji H. Inhibitory effects of TNF-alpha in engraftment of RA synovium into SCID mouse models. [Abstract]. Arthritis Rheum 1997;40 (suppl):S79.